Non-HDL Cholesterol and Evaluation of Cardiovascular Disease Risk

Area of Science:

• Cardiology
• Preventive Medicine
• Lipidology

Background:

• Cardiovascular disease (CVD) remains a leading global cause of mortality, particularly in developed nations.
• Current European and American Cardiological Association guidelines highlight non-high-density lipoprotein cholesterol (non-HDL-C) for CVD risk evaluation.
• Despite its recognized benefits, non-HDL-C is underutilized by general practitioners in routine lipid profiling.

Purpose of the Study:

• To review current information on the application of non-HDL-C in the primary prevention of cardiovascular disease.
• To compare the diagnostic utility of non-HDL-C against traditional and novel CVD risk factors.

Main Methods:

• Literature review of recent studies and guidelines on non-HDL-C.
• Comparative analysis of diagnostic performance metrics for non-HDL-C versus other risk factors.
• Synthesis of evidence regarding the role of non-HDL-C in primary CVD prevention strategies.

Main Results:

• Non-HDL-C offers a comprehensive measure of atherogenic lipoproteins.
• Evidence supports non-HDL-C as a valuable tool for refining CVD risk stratification.
• Comparison with traditional factors like LDL-C and novel markers is essential for clinical utility.

Conclusions:

• Increased adoption of non-HDL-C testing in primary care can improve CVD risk assessment.
• Further research should focus on optimal non-HDL-C targets and integration into clinical practice.
• Non-HDL-C represents a significant advancement in the primary prevention of cardiovascular disease.